Outcomes of tuberculosis treatment depending on cyp2c19 genotype
DOI:
https://doi.org/10.24959/cphj.14.1300Keywords:
tuberculosis, CYP2C19, treatment outcomeAbstract
As proven earlier, in patients with tuberculosis (TB) the concentration of antituberculosis drugs like isoniazid and rifampicin may differ depending on polymorphism of CYP2C19. The aim of the research was to determine the peculiarities of the pulmonary TB course and its outcome after the in-patient treatment depending on CYP2C19 genotype of the patients. The analysis of medical cards from 83 patients with the primary pulmonary tuberculosis at the end of the in-patient treatment in Odessa regional TB dispensary was conducted in 2012 with consideration of CYP2C19 genotype. At the beginning of the treatment the processes of disintegration were 3 times less in patients with *1/*1 genotype than in patients with *1/*2 genotype (10.3% versus 31.8%; P<0.05; χ2=5.40), and 6.5 times less than in individuals with *2/*2 genotype (10.3% versus 66.7%; P<0.05; χ2=7.94). At the end of the in-patient treatment the signs of pulmonary destruction were 6.5 times more common in individuals with *1/*1 genotype than in individuals with *1/*2 genotype (29.3 versus 4.5; Р<0.05; χ2=5.61). The signs of resorption and consolidation in the pulmonary tissue were observed in 74.1% of the patients with *1/*1 genotype, 95.5% of the patients with *1/*2 genotype and 66.7% of the patients with *2/*2 genotype. There were no significant differences between groups in relation to duration of the treatment and development of drug-resistance.
References
Антоненко П.Б., Кресюн В.Й. // Вісник наукових досліджень. – 2013. – №2. – С. 32-35.
Антоненко П.Б., Кресюн В.Й. // Одеський мед. журн. – 2013. – №5. – С. 16-20.
Мельник В.М., Новожилова І.О., Матусевич В.Г. та ін. // Укр. пульмонол. журн. – 2012. – №1. – С. 5-7.
Наказ МОЗ України №384 від 09.06.2006 р. «Про затвердження протоколу надання медичної допомоги хворим на туберкульоз»: Нормативні директивні правові документи. – К., 2006. – 87 с.
Фещенко Ю.І., Мельник В.М., Матусевич В.Г. та ін. // Укр. пульмонол. журн. – 2011. – №4. – С. 5-10.
Bertram G. Katzung’s Basic and Clinical Pharmacology. 12th Ed. – McGraw-Hill Education, 2012. – P. 842.
Dymova M.A., Liashenko O.O., Poteiko P.I. et al. // BMC Infect. Dis. – 2011. – №11. – Р. 77 (http://www. biomedcentral.com/1471-2334/11/77).
Falzon D., Jaramillo E., Schünemann H.J., Arentz M. // Eur. Respir. J. – 2011. – Vol. 38, №3. – P. 516-528.
Geetha Ramachandran, Soumya Swaminathan // Pharmacogenomics and Personalized Medicine. – 2012. – №5. – Р. 89-98.
Goldstein J.A., Blaisdell J. // Methods Enzymol. – 1996. – Vol. 272. – P. 210-218.
Mde J. Castillejos-López, García-Sancho M.C., Quiñones-Falconi F., Pérez-Padilla J.R. // Rev. Invest. Clin. – 2008. – Vol. 60, №1. – Р. 47-57.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
